Get started
Author

Doriane Cavalieri

Observed names: D Cavalieri, D. Cavalieri, Doriane Cavaliéri
Observed institutions: Inserm, Université Clermont Auvergne, Centre Hospitalier Universitaire de Lille, University of Oxford, Centre Hospitalier Universitaire de Clermont-Ferrand, Oxford University Hospitals NHS Trust, Centre Antoine Lacassagne, Hôpital Claude Huriez
ORCID: 0000-0002-4836-7237
Observed ORCID: 0000-0002-4836-7237
OpenAlex ID: A5083027357
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
2020 · Pierre Sesques, Emmanuelle Ferrant, et al. · American Journal of Hematology · 142
PDF
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
2022 · Pauline Robbe, Kate E. Ridout, et al. · Nature Genetics · 88
PDF
Monomorphic epitheliotropic intestinal T-cell lymphoma comprises morphologic and genomic heterogeneity impacting outcome
2022 · Luis Veloza, Doriane Cavalieri, et al. · Haematologica · 87
PDF
Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells
2021 · Pierre Sesques, Jérémie Tordo, et al. · Clinical Nuclear Medicine · 75
ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study
2022 · David Sibon, Bettina Bisig, et al. · Haematologica · 33
Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression
2024 · Léa Fléchon, Inès Arib, et al. · Blood Advances · 22
PDF
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
2021 · Amira Marouf, Anne Segolene Cottereau, et al. · Haematologica · 20
PDF
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines
2025 · Loïc Renaud, Marie Donzel, et al. · European Journal of Cancer · 18
PDF
Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma
2025 · David Vallois, Edoardo Missiaglia, et al. · Leukemia · 9
PDF
Antithrombotic therapy and platelet transfusions in hematologic malignancy patients presenting chemotherapy‐induced thrombocytopenia: a French survey
2017 · Emilie Chalayer, Doriane Cavalieri, et al. · Transfusion · 9
PDF
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma
2022 · Adrien Daniel, David Ghez, et al. · European Journal Of Haematology · 8
PDF
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study
2022 · Mark A. Catherwood, Dorte Wren, et al. · Frontiers in Oncology · 8
Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes
2023 · Guillaume Escure, Elise Fournier, et al. · Haematologica · 6
PDF
Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups
2020 · Amira Marouf, Anne Ségolène Cottereau, et al. · Blood · 5
Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA
2023 · A. Marouf, N. Molinari, et al. · British Journal of Haematology · 4
PDF
Impact of Dusp22 Rearrangement on the Prognosis of Systemic Alk‐negative Anaplastic Large Cell Lymphoma: a Lysa and Tenomic Study
2021 · D Sibon, B Bisig, et al. · Hematological Oncology · 4
PDF
Monomorphic Epitheliotropic Intestinal T‐cell Lymphoma (meitl): Clinico‐pathological Analysis of a Multicenter European Cohort
2021 · D. Cavalieri, O. Tournilhac, et al. · Hematological Oncology · 2
PDF
Correction: Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma
2025 · David Vallois, Edoardo Missiaglia, et al. · Leukemia · 1
PDF
Treatment options, responses and outcome of 1220 classic Hodgkin lymphoma patients included in realysa, a prospective multicentric lysa cohort
2025 · Herve Ghesquieres, Catherine Thieblemont, et al. · Blood · 1
PDF
High‐dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited‐stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial
2025 · Gotti Manuel, Yana Stepanishyna, et al. · HemaSphere · 1
PDF
Amahrelis : Adcetris Maintenance After Autologous Stem Cell Transplantation in Hodgkin Lymphoma : a Real Life Study From Sfgmtc and Lysa Groups
2021 · A. Marouf, A. S. Cottereau, et al. · Hematological Oncology · 1
PDF
The Genomic Landscape of Chronic Lymphocytic Leukaemia: Clinical Implications
2018 · Kate Ridout, Pauline Robbe, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Pre-treatment AMH levels suggesting PCOM do not prevent chemotherapy-induced ovarian damage despite higher long-term ovarian reserve: a longitudinal study in 467 women treated with alkylating agents
2026 · C Decanter, C Legrand, et al. · Human Reproduction
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma
2026 · Benjamin Podvin, Holly Lee, et al. · Blood Advances
Genomic loss of MLH1/PMS2 loci defines a mismatch repair deficient subgroup in monomorphic epitheliotropic intestinal T-cell lymphoma
2026 · Luis Veloza, Anja Fischer, et al. · Blood Cancer Journal
PDF
Works count: 41
Citation count: 545
H-index: 9
I10-index: 8
Year
Topic
Type